Search results
Results from the WOW.Com Content Network
Halozyme Therapeutics, Inc. is an American biotechnology company. It develops oncology therapies designed to target the tumor microenvironment . The company was founded in 1998 and went public in 2004.
The subcutaneous injection of atezolizumab and hyaluronidase was evaluated in IMscin001 (NCT03735121), an open-label, multi-center, international, randomized trial in adults with locally advanced or metastatic non-small cell lung cancer who were not previously exposed to cancer immunotherapy and who had disease progression following treatment with platinum-based chemotherapy. [2]
Small-caps and large-caps are wildly popular among investors, however, mid-cap stocks, such as Halozyme Therapeutics Inc (NASDAQ:HALO), with a market capitalization of US$2.2b, rarely draw their ...
This pharmacology -related article is a stub. You can help Wikipedia by expanding it.
Halozyme Therapeutics has had an incredible year, rallying more than 100% since the beginning of 2013. However, the ride up has been a very bumpy one, due to two major developments involving its ...
For premium support please call: 800-290-4726 more ways to reach us
What: Shares of Halozyme Therapeutics , a. Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're ...
What: Shares of Halozyme Therapeutics (NAS: HALO) Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they ...